N-terminal pro-brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure

Rada Vučić; Vladimir Ignjatović; Olivera Andrejić; Katarina Čupić; Miodrag Srećković; Filipović Vučković; Marija Sekulić; Milan Dobrić; Jelena Rakočević

doi:10.5937/afmnai42-53487

Original article

Published: 01.12.2024.

<< Prev | Next >>

PDF

https://doi.org/10.5937/afmnai42-53487

N-terminal pro-brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure

Abstract

Many markers are used to evaluate the prognosis in patients with acute myocardial infarction (AMI). Researches are focused on available markers with high sensitivity and specificity. The aim of our study was to evaluate the prognostic value of N-terminal pro brain natriuretic peptide (NT-proBNP) and its superiority compared with other prognostic markers in patients with AMI. Sixty-six patients with the diagnosis of AMI were enrolled in the study. The evaluated variables were: symptoms, cardiovascular risk factors, laboratory analyses (including NT-proBNP), GRACE risk score, electrocardiography, left ventricular ejection fraction (LVEF) and coronary angiography. One and six-month major adverse cardiovascular events (MACE) included: reAMI, heart rhythm disorders, acute heart failure, stroke, fatal event. Patients with one-month and six-month MACE were older, had anterior AMI, higher levels of NT-proBNP, urea, creatinine, lower LVEF, creatinine clearance (CCr) and hemoglobin level. NT-proBNP is an independent predictor of short-term (p = 0.002) and long-term (p = 0.000) prognosis. Its cut point of 1,467 pg/ml is a significant independent predictor of one-month MACE and cut point of 996 pg/ml is a significant independent predictor of six-month MACE. NT-proBNP is a strong short-term and long-term predictive marker in AMI patients without heart failure.

Keywords:

prognosis,

acute myocardial infarction,

NT‒proBNP

References

Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. Journal of the American College of Cardiology. 2002;39(2):210–8.

Vucic RM, Andrejic OM, Stokanovic D, Stoimenov TJ, McClements L, Nikolic VN, et al. Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure. Diagnostics. 13(21):3348.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237–69.

Omland T. Clinical and Laboratory Diagnostics of Cardiovascular Disease: Focus on Natriuretic Peptides and Cardiac Ischemia. Scandinavian Journal of Clinical and Laboratory Investigation. 2005;65(sup240):18–24.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation. 2004;110(20):3206–12.